Recent Antitrust Lessons For The Life Sciences Industry

Law360 (October 25, 2019, 1:57 PM EDT) -- The life sciences industry continues to face a steady flow of government and private plaintiff antitrust investigations and lawsuits, which at times has resulted in billion-dollar government fines, injunctive relief and class-wide damages. A common theme among these antitrust investigations and lawsuits is the use of internal company documents as some of the most damaging evidence. 

In many instances, internal documents tend to lack full context, may include ambiguous or colorful language and can reflect a single employee’s mistaken views. Plaintiffs frequently try to use such documents in an attempt to establish a genuine dispute of material fact for trial and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS